NWRN — Newron Pharmaceuticals SpA Income Statement
0.000.00%
Last trade - 00:00- CH₣287.54m
- CH₣296.03m
- €19.13m
Annual income statement for Newron Pharmaceuticals SpA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5.76 | 6.09 | 9.06 | 51.4 | 19.1 |
| Cost of Revenue | |||||
| Gross Profit | 5.64 | 5.65 | 8.59 | 50.5 | 17 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 18.1 | 19.4 | 20.7 | 25.2 | 23.8 |
| Operating Profit | -12.4 | -13.3 | -11.6 | 26.2 | -4.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -14.9 | -17.5 | -16.2 | 21.4 | -12.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14.9 | -17.5 | -16.2 | 15.8 | -13.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14.9 | -17.5 | -16.2 | 15.8 | -13.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -14.9 | -17.5 | -16.2 | 15.8 | -13.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.835 | -0.98 | -0.905 | 0.853 | -0.663 |